Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects

Abstract

The pharmacokinetics and safety of biapenem were studied in 36 healthy adult subjects in a randomized, placebo-controlled, double blind, sequential single- and multiple-ascending-dose study using doses from 250 to 1,250 mg administered three times a day using 3-h infusions. Maximum concentrations for biapenem were achieved at the end of the 3-h infusion.